[Translation] A dose-escalating, open-label Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of NV-A01 in the treatment of patients with advanced malignant solid tumors.
评价NV-A01单次与多次瘤内注射给药治疗晚期恶性实体瘤患者的安全性和耐受性,观察NV-A01的剂量限制性毒性(DLT),确定NV-A01的最大耐受剂量(MTD)以及Ⅱ期临床试验推荐剂量(RP2D)。
[Translation] To evaluate the safety and tolerability of single and multiple intratumoral injections of NV-A01 in the treatment of patients with advanced malignant solid tumors, observe the dose-limiting toxicity (DLT) of NV-A01, and determine the maximum tolerated dose of NV-A01 (MTD) and phase II clinical trial recommended dose (RP2D).